primary pdac cell lines panc 1  (ATCC)

Journal: Cancers

Article Title: Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth

doi: 10.3390/cancers17071152

Figure Lengend Snippet: Combined targeting of PI3K and MAPK pathways inhibits proliferation and colony forming ability of PDAC cells in vitro. Changes in cell proliferation in response to either OmiTram ( A ) or OmiSHP ( B ) treatment for 24 h was measured via the EdU assay. K8484 cells were treated with 5 nM Omipalisib, 10 nM Trametinib, and/or 50 μM SHP099. PKT62 cells were treated with 25 nM Omipalisib, 10 nM Trametinib, and/or 20 μM SHP099. MiaPaCa-2 cells were treated with 25 nM Omipalisib, 1 nM Trametinib, and/or 20 μM SHP099. Panc1 cells were treated with 25 nM Omipalisib, 1 nM Trametinib, and 20 μM SHP099. n = 4 wells for all groups. (* p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001). Changes in colony-forming ability in response to either OmiTram ( C ) or OmiSHP ( D ) treatment was measured via absorbance after crystal violet stain dissolution. K8484 cells were treated with 5 nM Omipalisib, 10 nM Trametinib, and/or 20 μM SHP099. PKT62 cells were treated with 5 nM Omipalisib, 10 nM Trametinib, and/or 2 μM SHP099. MiaPaCa2 cells were treated with 5 nM Omipalisib, 5 nM Trametinib, and/or 20 μM SHP099. Panc1 cells were treated with 50 nM Omipalisib, 20 nM Trametinib, and/or 50 μM SHP099. n = 3 wells for all groups (ns = not significant ( p ≥ 0.05), * p < 0.05, ** p <0.01, *** p < 0.001, and **** p < 0.0001). Error bars are shown ±SD.

Article Snippet: MiaPaCa-2 (#CRL-1420) and Panc1 (#CRL-1469) are primary human PDAC tumor cell lines purchased from ATCC (Manassas, VA, USA).

Techniques: In Vitro, EdU Assay, Staining, Dissolution

Journal: Cancers

Article Title: Combined Omipalisib and MAPK Inhibition Suppress PDAC Growth

doi: 10.3390/cancers17071152

Figure Lengend Snippet: Combined targeting of PI3K and MAPK pathways inhibits the migratory ability of PDAC cells in vitro. Changes in the migratory ability after treatment with either OmiTram ( A ) or OmiSHP ( B ) was assessed via the scratch migration assay over 24 h. K8484 cells were treated with 5 nM Omipalisib, 5 nM Trametinib, and/or 50 μM of SHP099. PKT62 cells were treated with 10 nM Omipalisib, 10 nM Trametinib, and/or 50 μM of SHP099. MiaPaCa2 cells were treated with 25 nM Omipalisib, 20 nM Trametinib, and/or 20 μM SHP099. Panc1 cells were treated with 5 nM Omipalisib, 20 nM Trametinib, and/or 20 μM SHP099. n = 4–6 wells for all groups (ns = not significant ( p ≥ 0.05), * p < 0.05, ** p <0.01, *** p < 0.001, and **** p < 0.0001). Error bars are shown ±SD.

Article Snippet: MiaPaCa-2 (#CRL-1420) and Panc1 (#CRL-1469) are primary human PDAC tumor cell lines purchased from ATCC (Manassas, VA, USA).

Techniques: In Vitro, Migration